TY - THES A1 - Dippong, Martin T1 - Direkte und indirekte Hapten-selektive Immunfluoreszenzmarkierung von Hybridomzellen zur Generierung monoklonaler Antikörper T1 - Direct and indirect hapten-specific immunofluorescence labeling of hybridoma cells for the generation of monoclonal antibodies N2 - Die Hybridomtechnik zur Produktion von monoklonalen Antikörpern ermöglichte einen großen Schritt in der Entwicklung von Immunoassays für die biochemische Forschung und klinische Diagnostik. Auch die Produktion von Antikörpern gegen niedermolekulare Analyten, Haptene, typische Targets in der Lebensmittel- und Umweltanalytik, erlangte in den letzten Jahren eine immer größere Bedeutung. Im Zuge der Durchführung der Hybridomtechnik werden tausende Antikörper-sezernierende und nicht-sezernierende Zellen generiert. Die Selektion der wenigen antigenselektiven Hybridomzellen zählt dabei zu den herausforderndsten Schritten für die Antikörpergewinnung. Bisherige Selektionsverfahren, wie die Limiting-Dilution-Klonierung in Verbindung mit Enzyme-linked Immunosorbent Assays (ELISAs), garantieren keine Monoklonalität und erlauben nur das Screening von einigen wenigen Zellklonen. Hingegen ermöglichen Hochdurchsatz-Selektionsmethoden, wie die Fluoreszenz-aktivierte Zellsortierung (FACS), einen sehr hohen Probendurchsatz. Eine Einzelzellablage garantiert hierbei Monoklonalität. Jedoch sind die dafür erforderlichen Zellmarkierungen oftmals zellschädigend oder aufwendig zu generieren. Auch ist bisher noch keine Markierungsmethode bekannt, die es ermöglicht, Hapten-selektive Hybridomzellen durchflusszytometrisch zu analysieren und eine FACS-Selektion durchzuführen. Aus diesem Grund wurden in dieser Arbeit zwei Zellmarkierungsmethoden entwickelt, die dies ermöglichen sollten. Die membranständigen Antikörper von Hybridomzellen sollten entweder direkt oder indirekt immunfluoreszenz-markiert und dadurch für die Durchflusszytometrie und FACS-Selektion zugänglich gemacht werden. Die direkte Markierung wurde mittels eines Hapten-Fluorophor-Konjugats durchgeführt. Sie ermöglichte erstmalig den Anteil an Haptenselektiven Hybridomzellen in einer Hybridomzelllinie zu überprüfen. Dies konnte für zwei Hapten-selektive Hybridomzelllinien, die Antikörper gegen das Hormon 17β-Estradiol und das Cardenolid Digoxigenin bilden, gezeigt werden. Durchflusszytometrie und ELISAs lieferten vergleichbare Ergebnisse. Zellen, die Hapten-selektiv markiert werden konnten, sezernierten ebenfalls Hapten-selektive Antikörper. Des Weiteren konnte die direkte Markierung dazu genutzt werden, zwei Mykotoxin-selektive Hybridomzelllinien, welche Antikörper gegen Aflatoxin und Zearalenon bilden, auf Monoklonalität zu testen. Dies ist mittels ELISA nicht möglich. Die Markierungsmethode eignete sich jedoch nur für fixierte Hybridomzellen. Eine Markierung von lebenden Zellen konnte weder durchflusszytometrisch noch mittels konfokaler Laser-Scanning-Mikroskopie gezeigt werden. Dies gelang erst mit einer neu entwickelten indirekten Immunfluoreszenzmarkierung. Dabei wurden die Zellen zunächst mit einem Hapten-Peroxidase-Konjugat inkubiert, gefolgt von einem Fluorophor-markierten anti-HRP-Antikörper-Konjugat. Dies wurde für zwei Analyten, das Hormon Estron und das Antiepileptikum Carbamazepin, gezeigt. Die indirekte Markierung wurde erfolgreich dazu verwendet, Carbamazepin-selektive Hybridomzellen aus einem Fusionsansatz für die monoklonale Antikörperproduktion auszusortieren. Damit wurde erstmalig eine Zellmarkierungsmethode entwickelt, die eine Hochdurchsatz-Selektion lebender Hybridomzellen aus einem Fusionsansatz ermöglicht. Sie ist nicht zellschädigend und kann zusätzlich zur Selektion Hapten-selektiver Plasmazellen verwendet werden. N2 - The ability to create monoclonal antibodies has allowed great strides to be made in immunoassay development for biochemical research and clinical diagnostics. Particularly for small molecular weight analytes, haptens, the need of selective antibodies has increased. The hybridoma technique generates thousands of fused antibody-secreting and non-secreting cells, with the majority being irrelevant. The subsequent screening and subcloning process in order to identify and isolate the very few hybrids that are secreting antibodies of the desired selectivity is a major concern. The traditional limiting dilution technique followed by enzymelinked immunosorbent assays (ELISAs) is inefficient and monoclonality is not guaranteed. Often the number of clones that can be screened is limited. High-throughput techniques such as fluorescence-activated cell sorting (FACS) provide an efficient tool to increase the number of cells to be screened. Furthermore, a single-cell deposition of cells would ensure monoclonality. However, antigen-selective cell labeling techniques are often cell damaging or laborious. The purpose of this study was to explore a cell labeling technique enabling the hapten-selective analysis and isolation of hybridoma cells via FACS. This would reduce much of the effort that has currently to be employed in hybridoma generation. For this reason, a direct and indirect hapten-selective labeling technique was developed. For the direct labeling, a haptenfluorophore conjugate was generated. The conjugate was used to tag membrane-bound immunoglobulin G of hybridoma cells and thereby enabling flow cytometric analysis. Using this kind of conjugate, it was possible to examine the selective antibody expression of hybridoma cell lines producing antibodies against the hormone estradiol and the steroid digoxigenin. Flow cytometric analysis and ELISAs showed comparable results: Cells, which were tagged with the corresponding hapten-fluorophore conjugate also secreted hapten-selective antibodies. Furthermore, it was possible to check hybridoma cell lines producing antibodies against the mycotoxins aflatoxin and zearalenone for monoclonality, which is not possible with ELISA. However, the direct labeling technique was only applicable to fixed cells. Successful labeling of living cells could neither be detected by flow cytometry nor by confocal laser scanning microscopy. On the contrary, using the newly developed indirect labeling technique, flow cytometric analysis and selection of living cells by FACS was possible. Here, the cells were first incubated with a hapten-peroxidase conjugate followed by a fluorophore-conjugated anti-peroxidase antibody. The technique was established on a hybridoma cell line selective for the hormone estrone. Furthermore, this labeling technique enabled for the first time the sorting of hybridoma cells producing selective antibodies against the medication carbamazepine out of a fusion mixture with high efficiency. The selected clones were used for monoclonal antibody production. The indirect labeling is harmless for cells and could also be applied on haptenselective plasma cells. KW - Durchflusszytometrie KW - Haptene KW - monoklonale Antikörper KW - Hybridom KW - Immunfluoreszenz KW - flow cytometry KW - hapten KW - monoclonal antibodies KW - hybridoma KW - immunofluorescence Y1 - 2017 ER - TY - CHAP A1 - Démaris, Alise A1 - Grišić, Ana-Marija A1 - Huisinga, Wilhelm A1 - Walter, Reinisch A1 - Kloft, Charlotte T1 - Evaluation of dosing strategies of anti-TNF alpha monoclonal antibodies using pharmacokinetic modelling and simulation T2 - Journal of Crohn's and Colitis N2 - Background: Anti-TNFα monoclonal antibodies (mAbs) are a well-established treatment for patients with Crohn’s disease (CD). However, subtherapeutic concentrations of mAbs have been related to a loss of response during the first year of therapy1. Therefore, an appropriate dosing strategy is crucial to prevent the underexposure of mAbs for those patients. The aim of our study was to assess the impact of different dosing strategies (fixed dose or body size descriptor adapted) on drug exposure and the target concentration attainment for two different anti-TNFα mAbs: infliximab (IFX, body weight (BW)-based dosing) and certolizumab pegol (CZP, fixed dosing). For this purpose, a comprehensive pharmacokinetic (PK) simulation study was performed. Methods: A virtual population of 1000 clinically representative CD patients was generated based on the distribution of CD patient characteristics from an in-house clinical database (n = 116). Seven dosing regimens were investigated: fixed dose and per BW, lean BW (LBW), body surface area, height, body mass index and fat-free mass. The individual body size-adjusted doses were calculated from patient generated body size descriptor values. Then, using published PK models for IFX and CZP in CD patients2,3, for each patient, 1000 concentration–time profiles were simulated to consider the typical profile of a specific patient as well as the range of possible individual profiles due to unexplained PK variability across patients. For each dosing strategy, the variability in maximum and minimum mAb concentrations (Cmax and Cmin, respectively), area under the concentration-time curve (AUC) and the per cent of patients reaching target concentration were assessed during maintenance therapy. Results: For IFX and CZP, Cmin showed the highest variability between patients (CV ≈110% and CV ≈80%, respectively) with a similar extent across all dosing strategies. For IFX, the per cent of patients reaching the target (Cmin = 5 µg/ml) was similar across all dosing strategies (~15%). For CZP, the per cent of patients reaching the target average concentration of 17 µg/ml ranged substantially (52–71%), being the highest for LBW-adjusted dosing. Conclusion: By using a PK simulation approach, different dosing regimen of IFX and CZP revealed the highest variability for Cmin, the most commonly used PK parameter guiding treatment decisions, independent upon dosing regimen. Our results demonstrate similar target attainment with fixed dosing of IFX compared with currently recommended BW-based dosing. For CZP, the current fixed dosing strategy leads to comparable percentage of patients reaching target as the best performing body size-adjusted dosing (66% vs. 71%, respectively). KW - linical databases KW - crohn's disease KW - regimen KW - monoclonal antibodies KW - body surface area KW - infliximab KW - fat-free mass KW - certolizumab pegol KW - body mass index procedure Y1 - 2020 U6 - https://doi.org/10.1093/ecco-jcc/jjz203.201 SN - 1873-9946 SN - 1876-4479 VL - 14 IS - Supp. 1 SP - S171 EP - S172 PB - Oxford Univ. Press CY - Oxford ER - TY - JOUR A1 - Holzlöhner, Pamela A1 - Hanack, Katja T1 - Generation of murine monoclonal antibodies by hybridoma technology JF - JoVE : Video journal N2 - Monoclonal antibodies are universal binding molecules and are widely used in biomedicine and research. Nevertheless, the generation of these binding molecules is time-consuming and laborious due to the complicated handling and lack of alternatives. The aim of this protocol is to provide one standard method for the generation of monoclonal antibodies using hybridoma technology. This technology combines two steps. Step 1 is an appropriate immunization of the animal and step 2 is the fusion of B lymphocytes with immortal myeloma cells in order to generate hybrids possessing both parental functions, such as the production of antibody molecules and immortality. The generated hybridoma cells were then recloned and diluted to obtain stable monoclonal cell cultures secreting the desired monoclonal antibody in the culture supernatant. The supernatants were tested in enzyme-linked immunosorbent assays (ELISA) for antigen specificity. After the selection of appropriate cell clones, the cells were transferred to mass cultivation in order to produce the desired antibody molecule in large amounts. The purification of the antibodies is routinely performed by affinity chromatography. After purification, the antibody molecule can be characterized and validated for the final test application. The whole process takes 8 to 12 months of development, and there is a high risk that the antibody will not work in the desired test system. KW - Immunology KW - Issue 119 KW - monoclonal antibodies KW - hybridoma technology KW - myeloma cells KW - B lymphocytes KW - antigen KW - immunconjugate Y1 - 2017 U6 - https://doi.org/10.3791/54832 SN - 1940-087X IS - 119 PB - JoVE CY - Cambridge ER -